Preimplantation Genetic Testing (PGT) has revolutionized the field of assisted reproductive technology (ART) by allowing for the genetic screening of embryos before implantation. This technology offers couples the opportunity to select healthy embryos and increase their chances of a successful pregnancy.

Preimplantation Genetic Screening (PGS)

PGS is designed to screen embryos for chromosomal abnormalities, such as aneuploidy. Aneuploidy occurs when there is an abnormal number of chromosomes, which can lead to conditions like Down syndrome or Turner syndrome.

Who might benefit from PGS?

• Advanced Maternal Age: Women over 35 are at increased risk of having children with chromosomal abnormalities.

• Recurrent Pregnancy Loss: Couples with a history of recurrent miscarriages may benefit from PGS to identify and select chromosomally normal embryos.

• Multiple Failed IVF Cycles: PGS can help identify and transfer healthy embryos, increasing the chances of a successful pregnancy.

Preimplantation Genetic Diagnosis (PGD)

PGD is a more specific test that screens embryos for specific genetic disorders. It is used when one or both parents are carriers of a genetic disease, such as cystic fibrosis, sickle cell anemia, or Huntington’s disease.

Who might benefit from PGD ?

• Couples with a family history of genetic disorders

• Couples who have previously had a child with a genetic disorder

• Couples who have undergone carrier screening and identified a genetic risk

By understanding the differences between PGS and PGD, embryologists can help couples make informed decisions about their fertility treatment options and increase their chances of having a healthy baby.